[Drug therapy as secondary prevention following myocardial infarction].
Cottier
C
C
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*; D012008:Recurrence
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D002317:Cardiovascular Agents; D001241:Aspirin
Medikamentöse Sekundärprophylaxe nach Myokardinfarkt.